We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+41.65%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$6.17B
AUM Growth
+$2.33B
Cap. Flow
+$258M
Cap. Flow %
4.18%
Top 10 Hldgs %
45.67%
Holding
151
New
35
Increased
25
Reduced
17
Closed
26

Top Buys

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$54.2M
2
LYRA
LYRA THERAPEUTICS INC
LYRA
+$47.1M
3
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$40.3M
4
ZGNX
Zogenix, Inc.
ZGNX
+$40.1M
5
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$38.9M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$102M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$53.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$36.9M
4
TBPH icon
Theravance Biopharma
TBPH
+$23.1M
5
NVRO
NEVRO CORP.
NVRO
+$22.8M

Sector Composition

Rank Sector Weight
1 Healthcare 82.05%
2 Financials 0.28%
3 Materials 0.1%
4 Technology 0.1%
5 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALBO
26
DELISTED
Albireo Pharma Inc
ALBO
$51.9M 0.84%
1,960,139
– –
NEPT
27
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$51.6M 0.84%
13,169
+3,571
+37% +$12M
ADMA icon
28
ADMA Biologics
ADMA
$2.02B
$48.6M 0.79%
16,584,802
– –
AGIO icon
29
Agios Pharmaceuticals
AGIO
$2.08B
$48.1M 0.78%
900,000
– –
RCKT icon
30
Rocket Pharmaceuticals
RCKT
$344M
$45.8M 0.74%
2,189,010
– –
ZNTL icon
31
Zentalis Pharmaceuticals
ZNTL
$330M
$45.8M 0.74%
+1,050,003
New +$40.3M
AGRX
32
DELISTED
Agile Therapeutics
AGRX
$44.3M 0.72%
7,960
– –
BDTX icon
33
Black Diamond Therapeutics
BDTX
$94.5M
$44M 0.71%
1,104,656
– –
VYNE icon
34
VYNE Therapeutics
VYNE
$39.6M 0.64%
6,355
+4,511
+245% +$30.5M
VRCA icon
35
Verrica Pharmaceuticals
VRCA
$88.8M
$37.5M 0.61%
341,041
– –
LYRA
36
DELISTED
LYRA THERAPEUTICS INC
LYRA
$36.5M 0.59%
+64,451
New +$47.1M
COLL icon
37
Collegium Pharmaceutical
COLL
$1.17B
$36M 0.58%
2,058,068
+506,346
+33% +$9.91M
MGNX icon
38
MacroGenics
MGNX
$235M
$36M 0.58%
+1,288,014
New +$22.4M
FUSN
39
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$36M 0.58%
+2,235,983
New +$38.9M
MTEM
40
DELISTED
Molecular Templates, Inc.
MTEM
$34.1M 0.55%
164,942
– –
NARI
41
DELISTED
Inari Medical, Inc. Common Stock
NARI
$33.7M 0.55%
+696,000
New +$33.2M
DBVT
42
DBV Technologies
DBVT
$819M
$32.1M 0.52%
731,781
– –
RNAM
43
DELISTED
Avidity Biosciences
RNAM
$31.6M 0.51%
+1,235,818
New +$35.6M
EIDX
44
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$30.1M 0.49%
686,922
– –
GERN icon
45
Geron
GERN
$905M
$29.3M 0.48%
+13,461,538
New +$20.1M
NVAX icon
46
Novavax
NVAX
$1.21B
$29.2M 0.47%
+350,000
New +$13.4M
TVTX icon
47
Travere Therapeutics
TVTX
$5.18B
$28.9M 0.47%
3,240,112
+349,504
+12% +$5.57M
PCVX icon
48
Vaxcyte
PCVX
$7.61B
$26.9M 0.44%
+850,000
New +$27.3M
IMVT icon
49
Immunovant
IMVT
$7.96B
$26.8M 0.43%
+1,100,000
New +$23.6M
ATRC icon
50
AtriCure
ATRC
$2.09B
$23.8M 0.39%
528,776
+226,549
+75% +$9.86M
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2020 Portfolio in Review

As of Q2 2020, Perceptive Advisors held 151 positions worth $6.17B, up 61% from $3.84B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors deployed $258M of net new capital in Q2 2020, opening 35 new positions and adding to 25 existing holdings. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 1,250,000 shares worth $58.1M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 95% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $102M trimmed.

  • Perceptive Advisors's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 1,250,000 shares worth $58.1M.
  • Perceptive Advisors added most to Zogenix, Inc. in Q2 2020, an estimated $40.1M increase.
  • Perceptive Advisors's biggest Q2 2020 reduction was Neurocrine Biosciences, cutting an estimated $102M.
  • Perceptive Advisors fully exited Theravance Biopharma in Q2 2020, selling an estimated $23.1M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $6.17B portfolio in Q2 2020.
  • Perceptive Advisors opened 35 new positions and closed 26 in Q2 2020.
  • Perceptive Advisors's portfolio value rose 61% quarter-over-quarter to $6.17B.

Based on Perceptive Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.